Madrigal has licensed a MASH drug candidate from Arrowhead for a total of $1 billion (approximately 1.45 trillion won). The RNAi therapy reduced liver fat by 46% after a single dose in patients with a specific genetic variant in a phase 1 trial. Madrigal plans to seek synergy wit
2026-05-06
Novo Nordisk raised its full-year outlook, buoyed by the strong performance of its oral obesity treatment Wegovy in the U.S. market. The revised forecast for the annual revenue decline was changed from 5%-13% to 4%-12%, while the forecast for adjusted operating profit was revised
2026-05-06
CellCentric has raised $220 million (approximately 319 billion won) in a Series D financing to develop inobrodib as a treatment for multiple myeloma. Inobrodib is an oral treatment for patients with relapsed multiple myeloma and may be particularly useful for patients who have re
2026-05-06
Differences in symptoms among patients with a chromosome 16p12.1 deletion appear to result from interactions with the broader genetic background beyond the eight genes. The research team identified this by differentiating patients’ induced pluripotent stem cells (iPSCs) into neur
2026-05-06
GSK has entered into a technology transfer agreement with China’s Xilan Bio to acquire the obesity treatment candidate SA030, with a total value of up to $1 billion, including an upfront payment of $55 million. SA030, an oligonucleotide-based drug candidate, targets ALK7 and is i
2026-05-06
Bayer will acquire Perfuze Therapeutics in a deal worth a total of 355 billion won, including an upfront payment of 43.5 billion won. Through the acquisition, Bayer secured PER-001, a Phase 2 ocular implant for the treatment of glaucoma and diabetic retinopathy. Bayer plans to st
2026-05-06
Eli Lilly will invest an additional $4.5 billion (approximately 6.5 trillion won) in its Indiana manufacturing complex to expand production of GLP-1 obesity treatments. The investment will be used to strengthen production of the active pharmaceutical ingredients (API) for Zepboun
2026-05-06
CellCentric has raised $220 million to develop the multiple myeloma drug inobrodib, which doubled the response rate compared with existing treatments. The oral p300/CBP inhibitor is expected to enter a global phase 3 trial in the second half of this year. The company said the fun
2026-05-06
Recursion Pharmaceuticals increased the efficiency of drug candidate discovery by up to 15-fold through its AI platform, while the oncology candidate REC-1245 demonstrated safety in an early clinical trial without dose-limiting toxicity. REC-1245 is an RBM39 protein degrader that
2026-05-06
Novo Nordisk has discontinued development of a single-formulation version of the GLP-1/amylin combination drug CagriSema but is maintaining its plan for a launch in early 2027. The treatment, which combines semaglutide and cagrilintide, is expected to be supplied through a dual-c
2026-05-06
